Pictet Asset Management Holding SA Buys 140,605 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Pictet Asset Management Holding SA grew its stake in NewAmsterdam Pharma (NASDAQ:NAMS) by 13.8% in the 4th quarter, Holdings Channel reports. The firm owned 1,157,452 shares of the company’s stock after purchasing an additional 140,605 shares during the period. Pictet Asset Management Holding SA’s holdings in NewAmsterdam Pharma were worth $29,747,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. FMR LLC raised its stake in NewAmsterdam Pharma by 35.6% in the third quarter. FMR LLC now owns 330,412 shares of the company’s stock worth $5,485,000 after buying an additional 86,712 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of NewAmsterdam Pharma by 1,231.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company’s stock worth $3,972,000 after acquiring an additional 221,305 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of NewAmsterdam Pharma by 176.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company’s stock valued at $371,000 after purchasing an additional 14,280 shares during the period. State Street Corp boosted its position in shares of NewAmsterdam Pharma by 168.7% during the third quarter. State Street Corp now owns 37,915 shares of the company’s stock valued at $629,000 after purchasing an additional 23,805 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in NewAmsterdam Pharma by 1.6% in the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock worth $1,433,000 after purchasing an additional 1,399 shares during the period. 89.89% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director James N. Topper acquired 1,135 shares of the business’s stock in a transaction that occurred on Wednesday, March 26th. The stock was bought at an average price of $22.49 per share, with a total value of $25,526.15. Following the completion of the acquisition, the director now directly owns 3,013,569 shares of the company’s stock, valued at approximately $67,775,166.81. The trade was a 0.04 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Louise Frederika Kooij sold 150,000 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,000 shares in the company, valued at approximately $305,550. This represents a 90.91 % decrease in their position. The disclosure for this sale can be found here. 19.50% of the stock is owned by insiders.

Analyst Ratings Changes

NAMS has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and set a $48.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Royal Bank of Canada reissued an “outperform” rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. UBS Group set a $41.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, March 3rd. Scotiabank boosted their price target on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research report on Thursday, February 27th. Finally, Needham & Company LLC reduced their price objective on NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a research report on Thursday, February 27th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $43.33.

NewAmsterdam Pharma Stock Down 2.9 %

Shares of NAMS opened at $21.76 on Monday. NewAmsterdam Pharma has a twelve month low of $15.19 and a twelve month high of $27.29. The company has a market capitalization of $2.39 billion, a P/E ratio of -8.37 and a beta of -0.04. The firm has a 50 day moving average of $21.66 and a 200 day moving average of $21.27.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.47). The business had revenue of $12.77 million during the quarter, compared to analyst estimates of $3.30 million. On average, sell-side analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current year.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.